Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:INO
- CUSIP: N/A
- Web: www.inovio.com
Capitalization:- Market Cap: $554.9 million
- Outstanding Shares: 90,227,000
Average Prices:- 50 Day Moving Avg: $5.73
- 200 Day Moving Avg: $6.65
- 52 Week Range: $5.28 - $9.86
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.26
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $51.84 million
- Price / Sales: 10.70
- Book Value: $1.59 per share
- Price / Book: 3.87
Profitability:- EBIDTA: ($70,600,000.00)
- Net Margins: -153.46%
- Return on Equity: -63.67%
- Return on Assets: -46.77%
Debt:- Current Ratio: 3.90%
- Quick Ratio: 3.90%
Misc:- Average Volume: 1.52 million shs.
- Beta: 2.75
- Short Ratio: 4.01
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm's revenue for the quarter was up 229.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.26) earnings per share. View Inovio Pharmaceuticals' Earnings History.
Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?
10 analysts have issued 12-month price objectives for Inovio Pharmaceuticals' stock. Their predictions range from $10.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $20.90 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.
What are analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
- 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), TG Therapeutics (TGTX), Spectrum Pharmaceuticals (SPPI), WAVE Life Sciences (WVE), Abeona Therapeutics (ABEO), ImmunoGen (IMGN), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP) and Celyad SA (CYAD).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
- Peter D. Kies, Chief Financial Officer
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer
- Mark L. Bagarazzi M.D., Chief Medical Officer
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
- George W. Bickerstaff III, Director
- David B. Weiner, Director
- Simon X. Benito, Independent Director
- Angel Cabrera Ph.D., Independent Director
Who owns Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.32%), Wasatch Advisors Inc. (2.89%), State Street Corp (2.40%), Northern Trust Corp (1.20%), Schwab Charles Investment Management Inc. (0.45%) and Bank of New York Mellon Corp (0.44%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Stoneridge Investment Partners LLC, New York State Common Retirement Fund, ING Groep NV, TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Russell Investments Group Ltd. and Teachers Advisors LLC. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.
Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Candriam Luxembourg S.C.A., GSA Capital Partners LLP, Vanguard Group Inc., Virtu KCG Holdings LLC, State of Wisconsin Investment Board, Public Employees Retirement System of Ohio and Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy Inovio Pharmaceuticals stock?
Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.15.
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $20.90 (239.84% upside) |
Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/22/2017 | HC Wainwright | Reiterated Rating | Buy | $13.00 | Low |  |
| 9/12/2017 | Maxim Group | Reiterated Rating | Buy | $12.00 | Low | |
| 9/6/2017 | Citigroup Inc. | Initiated Coverage | Buy -> Buy | $10.00 | High | |
| 7/18/2017 | Aegis | Reiterated Rating | Buy | $14.00 | Low | |
| 6/8/2017 | Piper Jaffray Companies | Upgrade | Neutral -> Overweight | $14.00 | Medium | |
| 5/25/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $11.00 | High | |
| 5/1/2017 | Nomura | Reiterated Rating | Buy | $40.00 | Low | |
| 5/1/2017 | Jefferies Group LLC | Reiterated Rating | Neutral | $38.00 | Low | |
| 5/1/2017 | BNP Paribas | Reiterated Rating | Neutral | $39.00 | Low | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $18.00 | N/A | |
| 6/21/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $17.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 17 | ($0.21) | ($0.13) | $16.29 million | $20.41 million | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.31) | ($0.31) | $5.83 million | $10.40 million | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.29) | ($0.35) | $5.21 million | $8.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.26) | ($0.28) | $5.16 million | $12.54 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.21) | ($0.26) | $4.95 million | $6.20 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.14) | ($0.11) | $4.75 million | $8.10 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.20) | ($0.25) | $6.96 million | $5.94 million | View | Listen | |
| 11/9/2015 | Q3 | $0.04 | $0.07 | $1.84 million | $24.18 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.13) | ($0.10) | $5.52 million | $5.30 million | View | Listen | |
| 5/11/2015 | Q1 | ($0.11) | ($0.18) | $7.04 million | $5.20 million | View | Listen | |
| 3/16/2015 | Q414 | ($0.10) | ($0.12) | $5.24 million | $2.50 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.11) | ($0.12) | $5.60 million | $1.80 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.17) | ($0.19) | $1.80 million | $3.80 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.04) | ($0.05) | $1.41 million | $2.40 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.03) | ($0.04) | $1.36 million | $1.70 million | View | N/A | |
| 11/11/2013 | Q3 | ($0.02) | ($0.16) | $2.99 million | $9.50 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.05) | ($0.05) | $2.07 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-1.17 EPS
Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 24.83%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
| Source: |
|
| Date | Headline |
|---|
 | Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 23 at 8:50 PM |
| Inovio Pharmaceuticals, Inc. (INO) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - September 23 at 2:26 PM |
| Inovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 22 at 5:44 PM |
 | ETF Preview: ETFs, Futures Mixed Following Weekly Jobless Claims, Philly Fed Manufacturing Data
www.nasdaq.com - September 21 at 4:07 PM |
 | Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection ... - GlobeNewswire (press release)
www.globenewswire.com - September 21 at 9:29 AM |
 | Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
finance.yahoo.com - September 21 at 9:29 AM |
| Inovio shares jump 5% premarket after two peer-reviewed paper support its research
finance.yahoo.com - September 21 at 9:29 AM |
 | Inovio Pharma (INO) and Its Partners Begin Phase 1/2a Trial to ... - StreetInsider.com
www.streetinsider.com - September 20 at 4:21 PM |
| Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : September 20, 2017
finance.yahoo.com - September 20 at 4:21 PM |
 | BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection
www.reuters.com - September 18 at 7:23 PM |
| Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
finance.yahoo.com - September 18 at 7:23 PM |
| Inovio Pharmaceuticals, Inc. (INO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 17 at 10:58 PM |
| Inovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - September 17 at 10:58 PM |
 | Inovio Pharmaceuticals (INO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 3:13 AM |
| INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study
globenewswire.com - September 11 at 8:38 PM |
 | Inovio Pharma Reports Promising Phase 1b Clinical Trial Data Of INO-5150
www.rttnews.com - September 11 at 8:38 PM |
| Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
finance.yahoo.com - September 11 at 8:38 PM |
| Inovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 10 at 8:16 PM |
| Inovio Pharmaceuticals, Inc. (INO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - September 9 at 4:16 PM |
| Surging Earnings Estimates Signal Good News for Inovio (INO)
finance.yahoo.com - September 7 at 8:11 PM |
| Is Inovio Pharmaceuticals Stock Poised for a Rebound?
finance.yahoo.com - September 6 at 6:25 AM |
| $14.04 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - September 6 at 3:16 AM |
 | Is Inovio Pharmaceuticals Stock Poised for a Rebound? - Motley Fool
www.fool.com - August 30 at 2:17 AM |
| Inovio Pharmaceuticals, Inc. (INO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 9:14 PM |
| Financial Review: Inovio Pharmaceuticals (INO) and Abeona Therapeutics (ABEO)
www.americanbankingnews.com - August 24 at 10:26 PM |
| Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
finance.yahoo.com - August 24 at 7:59 AM |
 | Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers - TheStreet.com
www.thestreet.com - August 22 at 12:07 AM |
| Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million
www.americanbankingnews.com - August 19 at 1:34 PM |
| -$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - August 17 at 8:18 AM |
| Inovio Pharmaceuticals, Inc. (INO) Short Interest Update
www.americanbankingnews.com - August 12 at 1:44 AM |
| Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - August 11 at 11:24 PM |
| Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Posts Earnings Results
www.americanbankingnews.com - August 10 at 4:04 PM |
| Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat - Nasdaq
www.nasdaq.com - August 9 at 8:09 PM |
| Edited Transcript of INO earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:40 AM |
| Inovio reports 2Q loss
finance.yahoo.com - August 9 at 5:40 AM |
| EARNINGS SUMMARY: Details of Inovio Pharmaceuticals Inc. Q2 Earnings Report
www.rttnews.com - August 9 at 12:37 AM |
| Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results - Nasdaq
www.nasdaq.com - August 8 at 7:34 PM |
| Here's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
finance.yahoo.com - August 8 at 7:34 PM |
| Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
finance.yahoo.com - August 8 at 7:34 PM |
| Here's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
www.fool.com - August 8 at 1:32 PM |
| Inovio: The Dilution Solution - Seeking Alpha
seekingalpha.com - August 8 at 5:26 AM |
| Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 4 at 8:44 PM |
| Report Coverage on Real Estate Stocks Inovalis REIT InterRent REIT BTB REIT and Dream Industrial REIT
finance.yahoo.com - August 4 at 8:09 PM |
| Inovio Pharmaceuticals, Inc. – Value Analysis (NASDAQ:INO) : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM |
| Analysts’ Recommendations for Regeneron in July 2017
finance.yahoo.com - August 1 at 3:29 PM |
| $18.75 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - August 1 at 8:53 AM |
| Analysts Expect Inovio Pharmaceuticals, Inc. (INO) to Announce -$0.18 EPS
www.americanbankingnews.com - July 30 at 7:42 AM |
| Inovio Pharmaceuticals, Inc. (INO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 3:35 PM |
 | How These Biotech Stocks are Performing? -- Inovio Pharma, Intra Cellular Therapies, OncoMed Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 11:20 PM |
| Inovio Pharmaceuticals to Report Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 28 at 3:47 AM |
Inovio Pharmaceuticals (INO) Chart for Sunday, September, 24, 2017
